PARP1 and non-small cell lung carcinoma: Recently, it was also shown that PARP-1 expression as well as PARylation levels were increased in non-small cell lung cancer cell lines resistant to cisplatin, as compared to their cisplatin-susceptible counterparts, indicating PARP-1 expression and activity may be correlated with tumor resistance to therapy [65].